Pieris Pharmaceuticals Inc (PIRS)
16.24
+0.12
(+0.74%)
USD |
NASDAQ |
Nov 13, 16:00
16.24
0.00 (0.00%)
After-Hours: 20:00
Pieris Pharmaceuticals Revenue (Annual): 42.81M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.81M |
| December 31, 2022 | 25.90M |
| December 31, 2021 | 31.42M |
| December 31, 2020 | 29.32M |
| December 31, 2019 | 46.28M |
| December 31, 2018 | 29.10M |
| Date | Value |
|---|---|
| December 31, 2017 | 25.28M |
| December 31, 2016 | 5.831M |
| December 31, 2015 | 2.563M |
| December 31, 2014 | 4.535M |
| June 30, 2014 | |
| December 31, 2013 | 9.880M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
25.90M
Minimum
2022
46.28M
Maximum
2019
35.15M
Average
31.42M
Median
2021
Revenue (Annual) Benchmarks
| Ligand Pharmaceuticals Inc | 131.31M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Palatin Technologies Inc | 4.490M |
| iBio Inc | 0.225M |
| Theriva Biologics Inc | -- |